基于IL-31衍生的WISIT疫苗作为慢性性皮肤病的新型治疗方法
Sabine Schmidhuber1, James Dickie2, Mihály Cserepes3
1Tridem Bioscience GmbH & CoKG, Campus Vienna Biocenter, Vienna, Austria.
PloS one
|February 11, 2025
概括
新型WISIT疫苗通过向中介IL-31来治疗慢性 (CP) 有望出现. 这些疫苗产生的抗体反应比传统的合疫苗更强,这表明皮肤疾病的可能性.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 疫苗开发 疫苗开发
背景情况:
- 慢性 (CP) 是一种使人衰弱的疾病,通常由介素-31 (IL-31) 介导.
- 传统的结合疫苗 (CCV) 由于免疫耐受性,对像IL-31这样的自我抗原无效.
- 新型赢得皮肤免疫系统技巧 (WISIT) 疫苗与CCV相比,已经显示出优异的抗体反应.
研究的目的:
- 为了比较WISIT疫苗与CCV在产生抗IL-31抗体反应方面的疗效.
- 评估WISIT疫苗在治疗IL-31介导慢性方面的潜力.
主要方法:
- 开发了WISIT和CCV,呈现了十种不同的IL-31特异性.
- 评估了抗体标位,抗体激活度和IL-31信号抑制.
- 在WISIT和CCV组之间比较免疫反应参数.
主要成果:
- 与CCV相比,WISIT疫苗诱导的抗体标位和狂热度显著更高.
- 在WISIT疫苗中,IL-31信号的抑制能力更强.
- 三种针对IL-31的WISIT候选疫苗被确定用于进一步开发.
结论:
- WISIT疫苗比CCV更具有免疫性,可以克服自身抗原耐受性.
- 威思特疫苗技术显示出治疗慢性等皮肤病的潜力.
- 对于已确定针对IL-31的WISIT候选疫苗,需要进行进一步的临床前研究.
相关概念视频
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
01:24T Cell Types and Functions
938
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
938